EUVIMEDEUVIMED entdecken
Crossref

Nature‐Inspired MYC Inhibitor Disrupts MYC‐Driven Glycolysis and Restricts Ovarian Tumor Growth

Mamta Singh, Anubha Yadav, Umesh Singh, Rajat Gupta, Enrico Cavarzerani, Vincenzo Canzonieri, Deepraj Negi, Akansha Dagar, Bharathwaj Sathyamoorthy, Flavio Rizzolio, Sushil Kumar, Ankur Baliyan und 2 weitere

ChemMedChem · 2026

DOI: 10.1002/cmdc.202500554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Mamta Singh und 13 weiteren Autor:innen. Beteiligte Einrichtung: Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Uttar Pradesh, 201313, India. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Glycolysis, Proto-Oncogene Proteins c-myc, Antineoplastic Agents. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myelocytomatosis oncogene (MYC) inhibitors are not available for clinical applications because the MYC protein is not part of a receptor‐ligand pair and lacks a defined binding site for small molecules. GD‐07, drug‐like small molecule identified throughcheminformatics that selectively binds to the G‐quadruplex (G4) in the c‐MYC promoter with high binding affinity and selectivity over dsDNA. NMR analysis reveals that GD‐07 binds to the upper tetrad of c‐MYC G4. It exhibits a favorable pharmacokinetic profile and high cytotoxicity in ovarian cancer (OC) cells (A2780) compared to the standard drug carboplatin. Normal cells show no sensitivity to GD‐07, indicating a broad therapeutic window. GD‐07 suppresses MYC expression, curbing glucose metabolism, and glycolysis while promoting p53 and proapoptotic markers in OC cells. In patient‐derived OC organoids, GD‐07 shows greater activity than carboplatin with promising clinical translatability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsGlycolysisProto-Oncogene Proteins c-mycAntineoplastic AgentsHumansFemaleCell ProliferationDrug Screening Assays, AntitumorMolecular StructureStructure-Activity RelationshipCell Line, TumorDose-Response Relationship, DrugG-QuadruplexesAnimalsApoptosisMice

Stichwörter der Autor:innen

G quadruplexMyelocytomatosis Oncogenecancer metabolismdrug discoveryovarian cancer

Substanzen

Proto-Oncogene Proteins c-mycAntineoplastic AgentsMYC protein, human

Autor:innen und Institutionen

  • Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Uttar Pradesh, 201313, India.
  • Department Biosciences and Bioengineering, Indian Institute of Technology Bombay, IIT Bombay, Powai, Mumbai, 400076, India.
  • Department of Molecular Sciences and Nanosystems, Ca' Foscari University of Venice, 30172, Venice, Italy.
  • Pathology Unit, Centro di Riferimento Oncologico di Aviano (C.R.O.) IRCCS, 33081, Aviano, Italy.
  • Department of Chemistry, Indian Institute of Science Education and Research, Bhopal, 462 066, India.
  • Graduate School of Nanobioscience, Yokohama City University, 22-2 Seto Kanazawa-ku, Yokohama, 236-0027, Japan.

ORCID-Profile: Reshma Rani

Zitieren

APA

Singh, M., Yadav, A., Singh, U., Gupta, R., Cavarzerani, E., Canzonieri, V., Negi, D., Dagar, A., Sathyamoorthy, B., Rizzolio, F., Kumar, S., Baliyan, A., Rani, R., & Kumar, V. (2026). Nature‐Inspired MYC Inhibitor Disrupts MYC‐Driven Glycolysis and Restricts Ovarian Tumor Growth. ChemMedChem. https://doi.org/10.1002/cmdc.202500554

Vancouver

Singh M, Yadav A, Singh U, Gupta R, Cavarzerani E, Canzonieri V, et al. Nature‐Inspired MYC Inhibitor Disrupts MYC‐Driven Glycolysis and Restricts Ovarian Tumor Growth. ChemMedChem. 2026. doi:10.1002/cmdc.202500554

BibTeX
@article{Singh2026,
  author = {Singh, Mamta and Yadav, Anubha and Singh, Umesh and Gupta, Rajat and Cavarzerani, Enrico and Canzonieri, Vincenzo and Negi, Deepraj and Dagar, Akansha and Sathyamoorthy, Bharathwaj and Rizzolio, Flavio and Kumar, Sushil and Baliyan, Ankur and Rani, Reshma and Kumar, Vinit},
  title = {Nature‐Inspired MYC Inhibitor Disrupts MYC‐Driven Glycolysis and Restricts Ovarian Tumor Growth},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.202500554}
}
Kostenlos starten →